Rephine HQ, UK
+44 1763 853135
Barcelona, Spain +34 934 178065
Menu
Over the past decades, the Life science industry has progressively introduced computer systems to support manufacturing, control and logistics processes. As a consequence, these became critical elements from the point of view of GxP regulations and, therefore, the Health Authorities have significantly increased their pressure on their role and on the data they manage.
As a result of this pressure, in regulatory inspections we can see an increasing number of observations related to computerized systems, with special relevance to those aspects related to Data Integrity. These observations can lead to serious problems with direct consequences on the business and corporate image.
In today’s competitive environment, reducing costs and increasing efficiency can be the key to a company’s survival. By adopting cloud-based systems, you can increase efficiency and prepare for future challenges with respect to data integrity and the expected amount of relevant data to be managed in the coming years.
In this situation, the regulated industry is forced to increase the technical approach in the validation of its computerized systems, as well as its management practices, in order to meet expectations in regulatory inspections.
Rephine is a global consulting company that is recognized as a pioneer and leader in the validation of computerised systems. Rephine always carried out these activities according to high technical and quality standards, aware of the applicable regulations, current practices and the needs of each client. These values have allowed the generation of methodologies, criteria and state-of-the-art documentation over time, which has satisfied the most stringent requirements of the inspectors in multiple audits of health authorities and clients.
We have a team of international consultants with extensive knowledge of the technologies and computer systems used in the pharmaceutical industry. Sensitive to the flexibility required by our clients, we adopt the role that best suits each case: from “turnkey” projects where the client’s effort is minimized, to ad-hoc consulting. Always providing a collaborative environment, in order to generate internal knowledge to guide their current practices and future decisions.
We provide extensive GMP consulting and regulatory services to help keep our clients ahead of the needs and expectations of regulators.
Article The strategic alliance will offer global pharmaceutical companies a streamlined, software-based solution to enhance quality assurance across their global supply chains San Francisco, February 28, …
Blog EUROPEAN COMMISSION PROPOSAL AMENDING MDR & IVDR TRANSITIONAL PROVISIONS (2023) On February 16 2023, the European Parliament finally voted on the EU Commission Proposal about …
Article Specialist GMP auditors will provide three speakers at the event, focusing on Good Manufacturing Practice, Quality Management Digitization, and GMP & Quality Data Integrity. …
Blog An appeal to the European health authority for leeway on the August 2023 compliance date has been rejected, putting the onus back on drug manufacturers …
Article Summary EU GMP Annex 1 requirements for Manufacture of Sterile Medicinal Products were revised in August 2022, starting the clock for compliance by August 2023. …
Article Pharma Manufacturing Transitions to Biotech and Personalized Therapies Drives Quality Process Innovation Article by Dr. Eduard Cayón, Rephine Published by Pharmaceutical Outsourcing The past decade …
Blog Bringing rigour to global supply chains as the reinvention of medicine continues by: Dr. Eduard Cayon, VP Audit Services, Rephine New waves of innovation in …
Ebook About this Ebook In August, the revised EU GMP Annex 1 requirements, related to the Manufacture of Sterile Medicinal Products, were issued, starting the clock for …
Telephone:
Rephine HQ, UK
+44 1763 853135
Barcelona, Spain +34 934 178065
Sign up to our newsletter to get the latest news about Rephine and industry news.